Bronchial asthma sufferers have many treatment choices, however many sufferers discover these decisions troublesome or insufficient in extreme instances of continual respiratory illness. Upstream Bio is pursuing a validated immunological goal with a drug that it claims provides dosing and efficacy benefits over a commercialized bronchial asthma drug from AstraZeneca and Amgen, and the biotech now has $225 million in […]